Reviving a Classic Antigen with a Cutting-Edge Approach: Nanobodies for HER2+ Breast Cancer.
HER2
breast cancer
nanobody
target therapy
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
26 May 2023
26 May 2023
Historique:
received:
29
03
2023
revised:
19
05
2023
accepted:
24
05
2023
medline:
28
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
The serendipitous discovery of nanobodies (NBs) around two decades ago opened the door to new possibilities for innovative strategies, particularly in cancer treatment. These antigen-binding fragments are derived from heavy-chain-only antibodies naturally found in the serum of camelids and sharks. NBs are an appealing agent for the progress of innovative therapeutic strategies because they combine the advantageous assets of smaller molecules and conventional monoclonal antibodies (mAbs). Moreover, the possibility to produce NBs using bacterial systems reduces manufacturing expenses and speeds up the production process, making them a feasible option for the development of new bio-drugs. Several NBs have been developed over the past 10 years and are currently being tested in clinical trials for various human targets. Here, we provide an overview of the notable structural and biochemical characteristics of NBs, particularly in their application against HER2, an extracellular receptor that often gets aberrantly activated during breast cancer tumorigenesis. The focus is on the recent advancements in diagnostic and therapeutic research up to the present date.
Identifiants
pubmed: 37375741
pii: ph16060794
doi: 10.3390/ph16060794
pmc: PMC10302560
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
N Engl J Med. 2020 Feb 13;382(7):610-621
pubmed: 31825192
J Extracell Vesicles. 2021 Feb;10(4):e12057
pubmed: 33643546
Semin Nucl Med. 2020 Jan;50(1):87-97
pubmed: 31843064
BMJ Case Rep. 2017 Mar 31;2017:
pubmed: 28363948
Oncol Lett. 2018 Jul;16(1):1259-1266
pubmed: 29963199
Semin Nucl Med. 2012 May;42(3):164-70
pubmed: 22475425
Int J Nanomedicine. 2021 Mar 22;16:2337-2356
pubmed: 33790553
Front Oncol. 2020 Jul 23;10:1182
pubmed: 32793488
Protein Eng Des Sel. 2021 Feb 15;34:
pubmed: 34908139
Nature. 1993 Jun 3;363(6428):446-8
pubmed: 8502296
EMBO J. 2000 Mar 1;19(5):921-30
pubmed: 10698934
Immunooncol Technol. 2020 Jul 09;7:2-14
pubmed: 35754459
Exp Hematol Oncol. 2021 Dec 18;10(1):56
pubmed: 34922633
Drugs Today (Barc). 2017 Nov;53(11):597-608
pubmed: 29451276
Drug Discov Today Technol. 2010 Summer;7(2):e95-e146
pubmed: 24103724
Theranostics. 2021 Mar 13;11(11):5525-5538
pubmed: 33859761
Science. 1987 Jan 9;235(4785):177-82
pubmed: 3798106
Biochim Biophys Acta. 2009 Aug;1794(8):1259-68
pubmed: 19348968
N Engl J Med. 2019 Jan 24;380(4):335-346
pubmed: 30625070
Antibodies (Basel). 2020 Mar 06;9(1):
pubmed: 32155903
Prostate Cancer. 2015;2015:285193
pubmed: 25802762
Cancer Cell Int. 2022 Jul 25;22(1):234
pubmed: 35879772
J Clin Oncol. 1993 Oct;11(10):1936-42
pubmed: 8105035
AMB Express. 2016 Dec;6(1):32
pubmed: 27112931
Clin Chem. 2016 Dec;62(12):1556-1564
pubmed: 27679436
J Mol Biol. 2018 Oct 19;430(21):4369-4386
pubmed: 30205092
FASEB J. 2011 Jul;25(7):2433-46
pubmed: 21478264
Pharmaceutics. 2022 Apr 08;14(4):
pubmed: 35456655
Clin Cancer Res. 2017 Nov 1;23(21):6616-6628
pubmed: 28751451
Nat Rev Drug Discov. 2020 Sep;19(9):589-608
pubmed: 32728208
Biophys J. 2000 Jan;78(1):394-404
pubmed: 10620303
FEBS J. 2021 Apr;288(7):2084-2102
pubmed: 32780549
Nature. 1995 Mar 9;374(6518):168-73
pubmed: 7877689
Transl Oncol. 2018 Apr;11(2):366-373
pubmed: 29455083
Curr Opin Oncol. 2021 Sep 1;33(5):493-499
pubmed: 34183491
J Control Release. 2020 Jan 10;317:34-42
pubmed: 31734445
Front Pharmacol. 2018 Mar 27;9:266
pubmed: 29636685
BioDrugs. 2020 Feb;34(1):11-26
pubmed: 31686399
Int J Mol Sci. 2023 Mar 22;24(6):
pubmed: 36983063
Antibodies (Basel). 2019 Mar 18;8(1):
pubmed: 31544831
ACS Chem Biol. 2022 Aug 19;17(8):2296-2303
pubmed: 35930411
Molecules. 2023 Feb 03;28(3):
pubmed: 36771161
Int J Nanomedicine. 2023 Apr 08;18:1915-1925
pubmed: 37064291
Nucl Med Biol. 2021 Jan;92:171-183
pubmed: 32448731
Proc Natl Acad Sci U S A. 2016 May 10;113(19):E2646-54
pubmed: 27091975
Bioimpacts. 2013;3(1):1-4
pubmed: 23678463
Lancet. 2017 Jun 17;389(10087):2415-2429
pubmed: 27939064
J Biomed Nanotechnol. 2018 Jan 1;14(1):1-19
pubmed: 29463363
Hum Antibodies. 2009;18(3):81-100
pubmed: 19729803
Br J Cancer. 2001 Jul 20;85(2):152-6
pubmed: 11461069
Theranostics. 2014 Jan 29;4(4):386-98
pubmed: 24578722
Mol Pharm. 2021 Sep 6;18(9):3616-3622
pubmed: 34328338
Cancer Lett. 2017 Jan 28;385:137-143
pubmed: 27815036
Angew Chem Int Ed Engl. 2018 Feb 23;57(9):2314-2333
pubmed: 28913971
Int J Mol Sci. 2021 Jun 07;22(11):
pubmed: 34200484
J Liposome Res. 2019 Mar;29(1):53-65
pubmed: 29621912
Annu Rev Biochem. 2013;82:775-97
pubmed: 23495938
J Nucl Med. 2023 Jan;64(1):124-130
pubmed: 35618478
Semin Immunol. 2021 Feb;52:101425
pubmed: 33272897
Cancers (Basel). 2021 Aug 25;13(17):
pubmed: 34503097
Front Oncol. 2021 May 12;11:669393
pubmed: 34055637
Front Mol Biosci. 2023 Mar 02;10:1144817
pubmed: 36936995
Chem Commun (Camb). 2019 Apr 25;55(35):5175-5178
pubmed: 30984937
Adv Mater. 2022 Sep;34(36):e2203224
pubmed: 35853614
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 Jul;13(4):e1697
pubmed: 33470555
Ophthalmic Res. 2022 Sep 14;:
pubmed: 36103843
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1371-1389
pubmed: 33179151
Expert Opin Biol Ther. 2013 Aug;13(8):1149-60
pubmed: 23675652
Cancer Res. 1992 May 1;52(9 Suppl):2747s-2751s
pubmed: 1563006
Drugs Today (Barc). 1999 Dec;35(12):931-46
pubmed: 12973420
Trends Biochem Sci. 2001 Apr;26(4):230-5
pubmed: 11295555
Eur J Nucl Med Mol Imaging. 2013 Oct;40(11):1718-29
pubmed: 23778558
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
Drugs. 2016 Jan;76(1):147-54
pubmed: 26620366
Int J Mol Sci. 2019 Nov 04;20(21):
pubmed: 31690044
EJNMMI Res. 2021 Jan 19;11(1):6
pubmed: 33464410
Nucl Med Biol. 2016 Apr;43(4):247-52
pubmed: 27067045
Hum Gene Ther Clin Dev. 2016 Jun;27(2):57-61
pubmed: 27267267
Nanomedicine (Lond). 2015 Jan;10(1):161-74
pubmed: 25597775
Mol Pharm. 2019 Apr 1;16(4):1633-1647
pubmed: 30817164
Mol Imaging Biol. 2019 Oct;21(5):898-906
pubmed: 30671739
Front Immunol. 2017 Nov 22;8:1603
pubmed: 29213270
Cancer Res. 2001 Jun 15;61(12):4750-5
pubmed: 11406547
Sci Rep. 2022 Feb 22;12(1):3020
pubmed: 35194100
Med Res Rev. 2023 May 11;:
pubmed: 37165896
Nano Today. 2009 Oct 1;4(5):399-413
pubmed: 20161038
Nucl Med Biol. 2018 Jan;56:10-20
pubmed: 29031230
Adv Sci (Weinh). 2022 Nov;9(33):e2203949
pubmed: 36220339
Front Immunol. 2017 Nov 02;8:1442
pubmed: 29163515
Med Lett Drugs Ther. 2018 Jul 16;60(1551):e122-e123
pubmed: 30036350
Curr Drug Discov Technol. 2015;12(1):3-20
pubmed: 26033233
Cancer Med. 2016 Dec;5(12):3454-3463
pubmed: 27882700
Curr Opin Struct Biol. 2017 Aug;45:10-16
pubmed: 27865111
Mol Ther. 2012 Oct;20(10):1831-2
pubmed: 23023051
Sci Rep. 2017 Oct 30;7(1):14289
pubmed: 29084989
J Nucl Med. 2016 Jan;57(1):27-33
pubmed: 26449837
Biochim Biophys Acta. 2013 Oct;1834(10):2147-57
pubmed: 23911607
FEBS Lett. 1997 Sep 15;414(3):521-6
pubmed: 9323027
Asia Pac J Oncol Nurs. 2018 Apr-Jun;5(2):137-155
pubmed: 29607374